Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Fat Stem CellsRNL BIO sumitted IND for pase II and III clinical trial to Korea FDA to treat cerebral palsy using autologous fat derived stem cells.
By: RNL BIO CO KR RNL-Astrostem™ Cerebral Palsy is caused by non-progressive brain damage from single or multiple defect(s) on nerce/muscular system and results in disorder in motion and sensory integration. According to Health Insurance Review and Assessment Service, the prevalence of cerebral palsy is 3.5 per 1000 male to 2.8 per 1000 female children, averaged at 3.2 per 1000 children, which is expected to increase due to reduction of premature death. In the clinical study investigators employ a variety of methods to assess efficacy: K-ABC:Kaufman Assessment Battery for Children, Gross Motor Function Measure(GMFM) Dr. JC Ra, president of RNL BIO Stem Cell Technology Institute, said, "It is our mission to find cures for incurable diseases, such as the terrible pediatric curse of cerebral palsy, through autologous stem cell technology." End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|